Enuzovimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A neutralizing monoclonal antibody directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, enuzovimab specifically targets and binds to the SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.

**Synonyms:** - Anti-SARS-CoV-2 S Protein Monoclonal Antibody HFB30132A - Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody HFB30132A - ENUZOVIMAB - HFB 30132A - HFB-30132A - HFB30132A